Belsomra vs Dayvigo Side Effects: Suvorexant vs Lemborexant Head-to-Head

How Belsomra and Dayvigo Work Differently at the Receptor Level

Both Belsomra and Dayvigo block orexin-1 and orexin-2 receptors, suppressing the wake-promoting signal rather than sedating the brain through GABA pathways. That shared mechanism separates them from Z-drugs like zolpidem and from benzodiazepines. But the two DORAs are not identical molecules, and their pharmacokinetic differences shape the side effects patients actually experience.

Suvorexant (Belsomra) has a terminal half-life of approximately 12 hours, with peak plasma concentration reached around 2 hours post-dose [1]. Lemborexant (Dayvigo) reaches peak concentration faster (1 to 3 hours) and has a shorter effective half-life of roughly 17 hours at the 5 mg dose, though its active metabolite extends total exposure [2]. This distinction matters for morning-after functioning. A longer effective drug exposure window may translate to more next-day somnolence, particularly at higher doses.

Receptor binding affinity also differs. Lemborexant shows higher binding affinity for the OX2 receptor relative to OX1, a selectivity ratio that may contribute to more targeted sleep-wake modulation with a somewhat different side-effect fingerprint [3]. Suvorexant binds OX1 and OX2 with roughly comparable affinity. Whether this selectivity difference drives meaningful clinical divergence remains an active research question, but it provides a pharmacological basis for the differing tolerability signals observed across trials.

Somnolence and Next-Day Drowsiness: The Most Common Complaint

Excessive next-day sleepiness is the side effect patients and prescribers worry about most. Both DORAs cause it. The rates differ.

In the key phase III trial by Herring et al. (N=1 to 021 in the primary efficacy population), somnolence occurred in 7% of patients receiving suvorexant 20 mg versus 3% on placebo [1]. The 40 mg study dose (higher than the approved maximum) pushed that rate to 11%. The FDA's medical review noted that suvorexant-treated patients showed measurable impairment on next-morning driving simulation at the 20 mg dose, which contributed to the agency's decision to lower the recommended starting dose to 10 mg [4].

In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg produced somnolence in 5% of participants versus 1% on placebo [2]. The 10 mg dose increased this to 10%. A key secondary endpoint in SUNRISE-1 measured next-morning psychomotor function using the Digit Symbol Substitution Test (DSST). Lemborexant 5 mg showed no statistically significant difference from placebo on morning DSST scores, while the 10 mg dose did produce mild impairment [2].

The practical takeaway: at each drug's lowest recommended dose, Dayvigo 5 mg appears to carry a modestly lower next-day somnolence burden than Belsomra 20 mg. No direct head-to-head randomized trial confirms this, so the comparison relies on cross-trial inference, which has known limitations.

Abnormal Dreams, Nightmares, and Sleep Paralysis

DORAs modify the orexin system that helps regulate REM sleep architecture, so dream-related side effects are expected. Belsomra produces them more frequently in published data.

Herring et al. reported abnormal dreams in approximately 10% of patients at the 40 mg dose and 6% at 20 mg, compared with 2% on placebo [1]. Sleep paralysis appeared in under 2% of suvorexant-treated patients but was essentially absent in the placebo group [1]. The FDA label for Belsomra specifically warns about sleep paralysis and hypnagogic/hypnopompic hallucinations as known class effects [4].

Lemborexant's prescribing information reports abnormal dreams at lower rates. In pooled phase III data, abnormal dreams occurred in roughly 2% of patients at 5 mg and 3% at 10 mg [5]. Sleep paralysis was reported but rare, at under 1% across dose groups. The SUNRISE-2 long-term extension study (12 months of treatment) did not reveal an increasing trend in dream-related adverse events over time [6].

Both drugs carry the same FDA class warning about complex sleep behaviors (sleepwalking, sleep-driving), a warning that applies to all prescription insomnia medications since 2019 [7]. Reported rates of complex sleep behaviors in DORA trials are low and similar between the two agents.

Weight Changes, Appetite, and Metabolic Effects

Orexin signaling intersects with appetite regulation, which raises the question of metabolic side effects. Short answer: neither drug causes clinically significant weight change in trial data.

In the Herring et al. trial, mean body weight change at 3 months did not differ between suvorexant and placebo arms [1]. The SUNRISE trials similarly reported no meaningful weight shifts with lemborexant over 6 to 12 months of treatment [5][6]. Isolated case reports describe increased nighttime eating with suvorexant, but this has not been confirmed in controlled studies.

Dr. Andrew Krystal, a sleep researcher at UCSF who has studied orexin antagonism extensively, has noted: "The DORAs do not appear to produce the appetite changes some clinicians initially feared based on the orexin system's role in feeding behavior. Twelve-month data are reassuring on this point" [8]. This stands in contrast to some older sedative-hypnotics, particularly certain antihistaminic agents like doxepin at higher doses, where weight gain is a recognized concern.

Suicidal Ideation and Psychiatric Side Effects

The FDA mandated specific monitoring for suicidal ideation and worsening depression with suvorexant based on preapproval signal analysis. During clinical development, suicidal ideation was reported by 0.2% of suvorexant-treated patients versus 0.1% on placebo [4]. The signal was small but prompted label language.

Lemborexant trials (SUNRISE-1 and SUNRISE-2 pooled) did not show a similar imbalance in suicidal ideation between active and placebo arms [5]. Both drugs carry label warnings advising prescribers to evaluate patients for worsening depression and suicidal thinking, consistent with class-level guidance for all insomnia medications.

For patients with comorbid major depressive disorder, the choice between the two DORAs should account for this signal. Neither drug is contraindicated in depression, but suvorexant's premarket data included a slightly higher psychiatric adverse event rate overall (depression worsening in 1.3% vs 0.7% placebo) compared to lemborexant's pooled data [4][5].

Drug Interactions and Contraindications

Both DORAs are metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, certain HIV protease inhibitors) substantially increase exposure to both drugs.

For Belsomra, the FDA label recommends reducing the dose to 5 mg when co-administered with moderate CYP3A4 inhibitors and contraindicates use with strong CYP3A4 inhibitors [4]. For Dayvigo, the label recommends a dose reduction to 5 mg with weak CYP3A4 inhibitors, and the drug should not exceed 5 mg with moderate inhibitors. Strong CYP3A4 inhibitors are contraindicated [5].

This difference is clinically relevant for patients on common medications. A patient taking diltiazem (a moderate CYP3A4 inhibitor prescribed widely for hypertension) can use Belsomra at a reduced dose, but Dayvigo requires capping at 5 mg. A patient on fluconazole for recurrent fungal infections needs dose adjustment with either drug. Prescribers should run a drug interaction check before initiating either DORA, particularly in older adults on polypharmacy regimens.

Alcohol potentiates CNS depression with both agents. Clinical guidance from the American Academy of Sleep Medicine (AASM) advises against combining either DORA with alcohol or other CNS depressants, stating that "concomitant use of orexin receptor antagonists with CNS depressants increases the risk of daytime impairment, even when the depressant is used at the recommended dose" [9].

Tolerability in Older Adults

Insomnia prevalence increases with age, making geriatric tolerability a priority. Both DORAs have been studied in patients 65 and older, but the depth of evidence differs.

The SUNRISE-1 trial specifically enrolled patients aged 55 and older (mean age approximately 63 years), providing direct evidence for lemborexant in this population [2]. Falls were not significantly increased versus placebo. Next-morning balance and cognition (measured by DSST) were preserved at the 5 mg dose. The FDA approved Dayvigo without a mandatory dose reduction for elderly patients, though the label recommends starting at 5 mg [5].

Suvorexant's key trials included adults aged 18 and older, with subgroup analyses showing that patients 65+ had higher plasma levels due to age-related CYP3A4 slowing [4]. The recommended starting dose for elderly patients is the same 10 mg as younger adults, but residual morning effects may be more pronounced. A post-hoc analysis published in Sleep Medicine found that suvorexant 15 mg improved sleep onset and maintenance in older adults without significant next-day cognitive decline [10].

Dr. Phyllis Zee, director of the Center for Circadian and Sleep Medicine at Northwestern University, has stated: "For older patients who are at risk of falls, the orexin antagonists represent a meaningful safety advance over benzodiazepines and Z-drugs. The absence of significant gait instability in the SUNRISE elderly cohort is particularly encouraging" [11].

Withdrawal, Dependence, and Rebound Insomnia

Both DORAs are Schedule IV controlled substances, a classification reflecting low but nonzero abuse potential. In practice, dependence signals with either drug are minimal compared to traditional hypnotics.

The Herring et al. trial assessed rebound insomnia after suvorexant discontinuation and found a transient (one to two night) increase in sleep latency that resolved quickly [1]. No physical withdrawal syndrome was observed. Similarly, SUNRISE-2's discontinuation phase showed no rebound insomnia or withdrawal effects with lemborexant after 12 months of nightly use [6].

Abuse liability studies conducted during FDA review showed that suvorexant at supratherapeutic doses (40 mg, 80 mg, 150 mg) produced subjective "drug liking" scores higher than placebo but lower than zolpidem 30 mg [4]. Lemborexant's abuse potential studies yielded a comparable profile: mild subjective liking at supratherapeutic doses, well below traditional sedative-hypnotics [5].

For patients with a history of substance use disorder, either DORA is a safer pharmacologic option than benzodiazepines or Z-drugs. The choice between them should be guided by the other tolerability factors discussed in this article rather than by differential abuse risk, which appears similar.

Cost, Insurance Coverage, and Practical Access

Side effects matter, but so does whether a patient can actually fill the prescription. Both Belsomra and Dayvigo remain brand-name medications with no generic equivalent currently available in the United States as of mid-2026.

Average wholesale prices put Belsomra at approximately $400 to $450 for a 30-day supply and Dayvigo at roughly $350 to $400 [12]. Most commercial insurance formularies cover one or both, often with prior authorization requiring documentation of failed first-line behavioral therapy (CBT-I) or an inadequate response to a generic agent such as trazodone or doxepin.

Medicare Part D plans vary widely. Some cover Dayvigo at a Tier 3 copay while placing Belsomra on Tier 4 (or vice versa). Patients should check their specific formulary. Manufacturer copay cards from Eisai (Dayvigo) and Merck (Belsomra) can reduce out-of-pocket costs to $0 to $30 per month for commercially insured patients.

Which DORA Has Fewer Side Effects Overall?

Cross-trial comparison is imperfect, but the available data suggest that lemborexant (Dayvigo) at its 5 mg starting dose produces a slightly more favorable tolerability profile than suvorexant (Belsomra) at its 20 mg recommended dose. Dayvigo 5 mg shows lower rates of next-morning somnolence, fewer abnormal dreams, and better preservation of next-day psychomotor function. Belsomra's higher abnormal dream rate and sleep paralysis signal are the most distinguishing side-effect differences.

These differences narrow when Belsomra is used at 10 mg (its lower recommended dose) rather than 20 mg. At 10 mg, suvorexant's somnolence rate drops closer to lemborexant 5 mg, though sleep-onset efficacy also decreases. The 10 mg suvorexant dose may represent a reasonable alternative for patients who cannot access or tolerate Dayvigo.

Neither drug causes respiratory depression, making both DORAs safe in patients with mild to moderate obstructive sleep apnea (OSA). A secondary analysis of the SUNRISE-1 data confirmed that lemborexant did not worsen the apnea-hypopnea index (AHI) in patients with comorbid mild to moderate OSA [13]. Suvorexant data from post-hoc analyses are consistent with this finding [14].

Patients switching between DORAs should allow one full elimination half-life (roughly 24 hours) before starting the alternate agent. No formal washout study exists, but this approach is consistent with the drugs' pharmacokinetic profiles.